Vasta, James D. http://orcid.org/0000-0001-8511-2113
Peacock, D. Matthew http://orcid.org/0000-0001-8558-5535
Zheng, Qinheng http://orcid.org/0000-0002-8440-8673
Walker, Joel A.
Zhang, Ziyang http://orcid.org/0000-0003-0541-7211
Zimprich, Chad A.
Thomas, Morgan R.
Beck, Michael T.
Binkowski, Brock F.
Corona, Cesear R.
Robers, Matthew B. http://orcid.org/0000-0001-8505-5227
Shokat, Kevan M. http://orcid.org/0000-0001-8590-7741
Funding for this research was provided by:
Promega Corporation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F32CA253966)
Damon Runyon Cancer Research Foundation (DRG-2434-21, DRG-2281-17)
Howard Hughes Medical Institute
Article History
Received: 14 October 2021
Accepted: 28 January 2022
First Online: 21 March 2022
Competing interests
: J.D.V., J.A.W., C.A.Z., M.R.T., M.T.B., B.F.B., C.R.C. and M.B.R. are employees of Promega Corporation, which holds patents related to the NanoBRET Target Engagement method. K.M.S. is an inventor on patents owned by University of California San Francisco covering KRAS targeting small molecules licensed to Araxes and Erasca. K.M.S. has consulting agreements for the following companies, which involve monetary and/or stock compensation: Revolution Medicines, Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics, Erasca, Genentech/Roche, Janssen Pharmaceuticals, Kumquat Biosciences, Kura Oncology, Mitokinin, Type6 Therapeutics, Venthera, Wellspring Biosciences (Araxes Pharma), Turning Point, Ikena, Initial Therapeutics and BioTheryX.